Short-course quinazoline drug treatments are effective in the Litomosoides sigmodontis and Brugia pahangi jird models. by Hübner, Marc P et al.
Contents lists available at ScienceDirect
IJP: Drugs and Drug Resistance
journal homepage: www.elsevier.com/locate/ijpddr
Short-course quinazoline drug treatments are eﬀective in the Litomosoides
sigmodontis and Brugia pahangi jird models
Marc P. Hübnera,∗, Emma Gundersonb, Ian Vogelb, Christina A. Bulmanb, K.C. Limb,
Marianne Koschela, Alexandra Ehrensa, Stefan J. Frohbergera, Martina Fendlera, Nancy Tricochec,
Denis Voroninc, Andrew Stevend, Victor Chie, Malina A. Bakowskie, Ashley K. Woodse,
H. Michael Petrassie, Case W. McNamarae, Brenda Beerntsenf, Laura Chappellg, William Sullivang,
Mark J. Taylord, Joseph D. Turnerd, Achim Hoeraufa, Sara Lustigmanc, Judy A. Sakanarib
a Institute for Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, Germany
bDept. of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA
c Laboratory of Molecular Parasitology, Lindsley F. Kimball Research Institute, New York Blood Center, New York, USA
d Centre for Drugs and Diagnostics, Dept. of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool, UK
e Calibr, a Division of The Scripps Research Institute, La Jolla, CA, USA
f Veterinary Pathobiology, University of Missouri-Columbia, Columbia, MO, USA
g Dept. of Molecular, Cell and Developmental Biology, University of California, Santa Cruz, CA, USA
A R T I C L E I N F O
Keywords:
Quinazoline
Litomosoides sigmodontis
Brugia pahangi
Filaria
Doxycycline
Wolbachia
Macroﬁlaricidal
Microﬁlariae
A B S T R A C T
The quinazolines CBR417 and CBR490 were previously shown to be potent anti-wolbachials that deplete
Wolbachia endosymbionts of ﬁlarial nematodes and present promising pre-clinical candidates for human ﬁlarial
diseases such as onchocerciasis. In the present study we tested both candidates in two models of chronic ﬁlarial
infection, namely the Litomosoides sigmodontis and Brugia pahangi jird model and assessed their long-term eﬀect
on Wolbachia depletion, microﬁlariae counts and ﬁlarial embryogenesis 16−18 weeks after treatment initiation
(wpt). Once per day (QD) oral treatment with CBR417 (50 mg/kg) for 4 days or twice per day (BID) with
CBR490 (25 mg/kg) for 7 days during patent L. sigmodontis infection reduced the Wolbachia load by> 99% and
completely cleared peripheral microﬁlaremia from 10–14 wpt. Similarly, 7 days of QD treatments (40 mg/kg)
with CBR417 or CBR490 cleared> 99% of Wolbachia from B. pahangi and reduced peritoneal microﬁlariae
counts by 93% in the case of CBR417 treatment. Transmission electron microscopy analysis indicated intensive
damage to the B. pahangi ovaries following CBR417 treatment and in accordance ﬁlarial embryogenesis was
inhibited in both models after CBR417 or CBR490 treatment. Suboptimal treatment regimens of CBR417 or
CBR490 did not lead to a maintained reduction of the microﬁlariae and Wolbachia load. In conclusion, CBR417
or CBR490 are pre-clinical candidates for ﬁlarial diseases, which achieve long-term clearance of Wolbachia
endosymbionts of ﬁlarial nematodes, inhibit ﬁlarial embryogenesis and clear microﬁlaremia with treatments as
short as 7 days.
1. Introduction
The neglected tropical disease known as onchocerciasis or river
blindness is caused by the ﬁlarial nematode Onchocerca volvulus. The
disease is characterized by adult worms residing in subcutaneous no-
dules and the release of microﬁlariae (mf) into the skin by the female
worms (Hoerauf et al., 2011). Disease pathology occurs as a result of mf
death in dermal and ocular tissues leading to release of somatic in-
ﬂammatory molecules including release of the ﬁlarial bacterial
endosymbiont,Wolbachia. Host immunopathology induced by liberated
antigens leads to onchodermatitis, keratitis and eventual visual im-
pairment (Saint Andre et al., 2002; Gillette-Ferguson et al., 2004;
Turner et al., 2009; Tamarozzi et al., 2011). Since the 1970s several
control programs, initially based on vector control, were conducted to
prevent the transmission of onchocerciasis but later included mass drug
administration (MDA) with ivermectin (IVM) (Hoerauf et al., 2011).
The recently stated sustainable development goal by the United Nations
is to eliminate the transmission of infection and disease, and thus
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eliminate onchocerciasis by 2030 (WHO, 2019). All current control
strategies for the control and elimination of onchocerciasis rely on MDA
of IVM, which temporarily inhibits embryogenesis within female adult
worms and thereby decreases transmission of mf. However, IVM has no
macroﬁlaricidal eﬃcacy, i.e. does not kill the adult worms, and there-
fore must be given annually or bi-annually over the reproductive life-
span of the adult worms, which can be up to 15 years for O. volvulus.
More recently, moxidectin has been implemented as a novel treatment
option for onchocerciasis. Moxidectin also targets the mf stage but leads
to a longer suppression of the microﬁlaridermia and is therefore ex-
pected to reduce the MDA rounds required (Opoku et al., 2018).
However, administration of the microﬁlaricides IVM and moxidectin by
MDA is an issue in areas co-endemic for loiasis, since Loa loa infections
with high microﬁlaremia (> 30,000 mf/mL) can lead to life-threa-
tening serious adverse events (SAEs) upon IVM administration (Gardon
et al., 1997; Taylor et al., 2010; Opoku et al., 2018). Thus, drugs that
can be safely administered in areas co-endemic for O. volvulus and L.
loa, i.e. those that have macroﬁlaricidal but no or little microﬁlaricidal
activity are critically needed to support the sustainable development
goal of eliminating onchocerciasis within the next 10 years.
O. volvulus, like most human-pathogenic ﬁlariae, harbors in-
tracellular endosymbiotic bacteria, Wolbachia, which are important for
the fecundity and viability of the ﬁlariae (Hoerauf et al., 1999, 2000).
Targeting Wolbachia with 4–6 weeks of doxycycline therapy leads to
permanent sterilization of the adult female ﬁlariae and provides mac-
roﬁlaricidal eﬃcacy over time (~2 years) (Hoerauf et al., 2001). Since
doxycycline was shown to be the ﬁrst safe macroﬁlaricidal drug
available and L. loa lacks Wolbachia endosymbionts (Büttner et al.,
2003; Grobusch et al., 2003; McGarry et al., 2003; Desjardins et al.,
2013), a major eﬀort was undertaken to identify anti-Wolbachia drug
candidates with an increased potency and shorter treatment regimens
(Bakowski and McNamara, 2019). Quinazolines represent such a novel
class of drug candidates with a potent anti-Wolbachia eﬃcacy. Recently,
two quinazolines, CBR417 and CBR490, were identiﬁed and optimized
through a primary cell-based high-content imaging screen and an ex
vivo worm-based validation assay (Bakowski et al., 2019). Both com-
pounds showed excellent anti-Wolbachia potency in vitro and ex vivo and
mediated rapid clearance of Wolbachia in in vivo rodent models of ﬁ-
lariasis (Bakowski et al., 2019). A structurally related azaquinazoline
candidate, AWZ1066S, has entered formal preclinical development
(Hong et al., 2019).
In this study, we further characterized the long-term eﬃcacy of
CBR417 and CBR490 in jirds chronically infected with the ﬁlarial ne-
matodes Litomosoides sigmodontis and Brugia pahangi. Our study de-
monstrates that mf initially decreased in numbers 8–10 weeks following
treatment, but they rebounded when animals were given sub-optimal
doses. However, higher optimal doses of the two anti-Wolbachia com-
pounds were eﬃcacious in inhibiting embryogenesis, decreasing the
number of mf and decreasing Wolbachia titers in adult female worms in
both animal models. Our studies therefore provide supporting evidence
to nominate these quinazoline compounds as preclinical drug candi-
dates for treatment of human ﬁlarial diseases.
2. Methods
2.1. Litomosoides sigmodontis in vivo studies
2.1.1. Animal infections
Female jirds (Meriones unguiculatus) 6- to 8-weeks of age were ob-
tained from Janvier Labs (Saint-Berthevin, France) and housed in in-
dividually ventilated cages at the animal facility of the Institute for
Medical Microbiology, Immunology and Parasitology, University
Hospital Bonn, in accordance with the European Union's animal welfare
guidelines. All protocols were approved by the Landesamt für Natur,
Umwelt und Verbraucherschutz, Cologne, Germany (AZ
84–02.04.2015.A507). For L. sigmodontis infection, jirds were exposed
to Ornithonyssus bacoti mites infected with infective third-stage larvae
(L3). All animals from one experiment were infected with the same
batch of mites to ensure equal infection rates. Only mf positive jirds
were included in the study and treatment started 13–16 weeks post-
infection (wpi). As jirds are highly susceptible for infection with L.
sigmodontis and harbor the infection for more than 1 year, diﬀerences in
the treatment start date by a few weeks do not aﬀect the outcome of the
study (Morris et al., 2013).
2.1.2. Drug formulations and dosages
Only mf positive jirds were included in the studies and received oral
gavages with 2.5 mL/kg of the formulated drugs. Doxycycline (Sigma-
Aldrich) was formulated in distilled water, and CBR417 as well as
CBR490 were provided by Calibr at Scripps Research and formulated in
40% cyclodextrine diluted in distilled water.
2.1.3. L. sigmodontis jird study I
Five experimental groups were tested in this study and treatment
was initiated 13 wpi (Table 1). Group 1 remained untreated and was
used as control (n = 6). Group 2 received bi-daily (BID) 40 mg/kg
doxycycline for 14 consecutive days (n = 6). Group 3 received 50 mg/
kg CBR417 once-per-day (QD) for 4 consecutive days (n = 6). Group 4
received 75 mg/kg CBR490 BID for 7 consecutive days (n = 6) and
group 5 received 25 mg/kg CBR490 BID for 7 consecutive days (n = 6).
Necropsies were performed at 18 weeks after the start of treatment
(weeks post-treatment, wpt). At necropsy L. sigmodontis adult worms
were isolated from the thoracic cavity and enumerated as previously
described (Hübner et al., 2019a).
2.1.4. L. sigmodontis jird study II
Eight experimental groups were tested in this study and treatment of
the animals started at 16 wpi (Table 2). Group 1 received an equal
volume of CBR vehicle for 14 days. Group 2 received 40 mg/kg dox-
ycycline BID for 14 consecutive days (n = 5). Group 3 received 50 mg/
kg CBR417 QD for 7 consecutive days (n = 5). Group 4 received
20 mg/kg CBR417 QD for 7 consecutive days (n = 6). Group 5 received
10 mg/kg CBR417 QD for 7 consecutive days (n = 6). Group 6 received
20 mg/kg CBR490 QD for 7 consecutive days (n = 6). Group 7 received
10 mg/kg CBR490 QD for 7 consecutive days (n = 6) and group 8
received BID treatments with 25 mg/kg CBR490 for 7 consecutive days
(n = 6). Necropsies were performed at 16 wpt and L. sigmodontis worms
were isolated and enumerated.
Table 1
Dosing regimen for L. sigmodontis-infected jirds in study I.
Group Treatment n = Dose (mg/kg) Daily doses Duration (d)
1 Untreated 6 – – –
2 Doxy 6 40 BID 14
3 CBR417 6 50 QD 4
4 CBR490 6 75 BID 7
5 CBR490 6 25 BID 7
Table 2
Dosing regimen for L. sigmodontis-infected jirds in study II.
Group Treatment n = Dose (mg/kg) Daily doses Duration (d)
1 Vehicle 6 – BID 14
2 Doxy 5 40 BID 14
3 CBR417 5 50 QD 7
4 CBR417 6 20 QD 7
5 CBR417 6 10 QD 7
6 CBR490 6 20 QD 7
7 CBR490 6 10 QD 7
8 CBR490 6 25 BID 7
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2.1.5. Microﬁlariae counts from peripheral blood
For mf counts, 10 μL of peripheral blood was taken from the sa-
phenous vein in bi-weekly intervals starting at 12 wpi, diluted in 190 μL
of red blood cell lysis buﬀer and stored at room temperature until
analysis (BioLegend, San Diego, CA, USA). After resuspension, 10 μL of
the suspension was transferred to a microscopic slide and mf were
counted using a microscope. If less than 10 mf were counted, the tube
was centrifuged at 400 g for 5 min. The supernatant was then discarded,
and the pellet was resuspended and completely transferred to a mi-
croscopic slide. Mf were counted in the sample using a microscope.
Results are presented as number of mf per 10 μL blood.
2.1.6. Necropsies
Necropsies were performed at 16 or 18 wpt. At necropsy, L. sigmo-
dontis worms were isolated from the thoracic cavity and quantiﬁed as
previously described (Hübner et al., 2019b). Brieﬂy, animals were eu-
thanized with an overdose of isoﬂurane and the peritoneum was
opened, followed by a small incision at the diaphragm. Adult worms
were collected by ﬂushing the thoracic cavity with PBS. Finally, the
pleural cavity was opened completely and inspected for remaining
worms. Male and female worms were separated and counted.
2.1.7. Embryograms
Female L. sigmodontis adult worms isolated at 16 and 18 wpi were
also analyzed for embryogenesis as previously described (Ziewer et al.,
2012). Single female adult worms were homogenized in 80 μL PBS and
20 μL Hinkelmann solution (0.5% eosin Y, 0.5% phenol, 0.185% for-
maldehyde in distilled water) and the developmental stages (eggs,
morulae, pretzel, and stretched mf) as well as degenerated embryonic
stages were enumerated using a light microscope.
2.1.8. qPCR analysis of Wolbachia from L. sigmodontis adult female worms
qPCR was performed to validate the depletion ofWolbachia bacteria
post-treatment using primers for the Wolbachia single copy gene ftsZ
(GenBank Accession No.: AJ010271) and the L. sigmodontis actin gene
(act) (GenBank Accession No.: GU971367) for normalization as pre-
viously described (Hübner et al., 2019b). For determination of the
Wolbachia ftsZ/act ratio in adult worms, 10 female worms per animal (if
present) were individually frozen at −20 °C for later analysis. DNA
from female adult worms was puriﬁed using the Qiagen Mini DNA
puriﬁcation kit according to the manufacturer's protocol. The PCR was
performed in triplicate by duplex real-time PCR using Qiagen's Quan-
tiNova® on a Rotorgene Q 5-Plex (Qiagen, Hilden, Germany). The fol-
lowing primer pairs (MicroSynth; Switzerland) and TaqMan probes
(biomers; Germany) were used: L. sigmodontis ftsZ forward 5′-CGATG
AGATTATGGAACATATAA-3′, L. sigmodontis ftsZ reverse 5′-TTGCAATT
ACTGGTGCTGC-3′, L. sigmodontis ftsZ TaqMan probe 5′6-FAM CAGGG
ATGGGTGGTGGTACTGGAA-3′TAMRA, L. sigmodontis act forward
5′-ATCCAAGCTGTCCTGTCTCT-3′, L. sigmodontis act reverse 5′-TGAGA
ATTGATTTGAGCTAATG-3′, L. sigmodontis act TaqMan probe 5′HEX
5′-ACTACCGGTATTGTGCTCGATT-3′TAMRA. The qPCR consisted of 45
cycles with a melting temperature of 95 °C for 5 s and an annealing
temperature of 58 °C for 30 s. The standard curve used was a mix of L.
sigmodontis ftsZ and act plasmids.
2.2. Brugia pahangi in vivo studies
2.2.1. Animal infections
Male jirds (Meriones unguiculatus) approximately 6 weeks of age
(50–60 g) were purchased from Charles River Laboratories
International, Inc., Wilmington, MA USA), and injected in-
traperitoneally with 200 B. pahangi L3 isolated in the Beerntsen la-
boratory. Animal studies were performed under the University of
California, San Francisco Institutional Animal Care and Use Committee
(IACUC) approvals AN109629-03 and AN173847-02 and adhered to the
guidelines set forth in the NIH Guide for the Care and Use of Laboratory
Animals and the USDA Animal Care Policies.
2.2.2. Drug formulations and dosages
CBR417 and CBR490 were provided by Calibr at Scripps Research
and dissolved in 40% beta-cyclodextrin at concentrations of 16 mg/mL,
8 mg/mL and 4 mg/mL. Dosing started 23 wpi with 5 groups of jirds:
Group 1 (n = 6) was given vehicle QD for 7 days; Group 2 (n = 6) was
given 40 mg/kg of CBR417 QD for 7 days; and Groups 3, 4 and 5 were
given 40 mg/kg, 20 mg/kg or 10 mg/kg of CBR490, respectively, QD
for 7 days (see Table 3).
2.2.3. Pharmacokinetic analyses of jird plasma
For PK sampling during jird/L. sigmodontis and B. pahangi eﬃcacy
experiments, whole blood was collected from the saphenous vein and
8 μL was spotted onto protein saver cards for dried blood spot (DBS)
analysis (Whatman 903, Cardiﬀ, UK), and plasma concentration of each
compound was determined using LC/MS. Cohorts of L. sigmodontis-in-
fected animals were sampled 1, 3, 7, and 24 h post-ﬁrst and -last
morning dose. During jird/B. pahangi eﬃcacy experiments, whole blood
was collected 3, 24, 48, and 96 h post-ﬁrst dose; then 0.5 h before the
last dose; and 3, 24, 48, and 96 h post-last dose. DBS cards were stored
at 4 °C prior to shipment to Accelera (Milano, Italy) for analysis.
2.2.4. Animal necropsies
Animals were necropsied 17 wpt. Adult worms and mf were re-
covered by opening the body cavity and washing the peritoneal cavity
with 100 mL of phosphate buﬀered saline (PBS). Male and female
worms were separated and counted and the number of mf present in the
peritoneal cavity was determined by staining with 0.04% methylene
blue and counting stained mf on a glass slide using a compound mi-
croscope. The mf counts were multiplied by the appropriate dilution
factor to calculate the total number of mf from each jird.
2.2.5. Embryograms
To study the eﬀect of treatment on embryogenesis, embryograms
were conducted on female worms from each group as previously de-
scribed (Ford et al., 2009). Each female worm was homogenized in
500 μL of PBS to release the contents of the uterus, followed by
counting 10 μL of the extracted embryonic stages using a compound
microscope and hemocytometer. At least 200 events were measured for
each female worm, and 3–4 females were analyzed per animal from 3–4
animals from each experimental group. The intra-uterine progeny were
expressed as the relative proportions of progeny at diﬀerent stages of
development; eggs, developing embryos, pre-microﬁlariae (pre-mf), mf
and degenerated embryonic stages.
2.2.6. Fluorescence in situ hybridization (FISH)-based quantiﬁcation of
Wolbachia within female worm ovaries
Adult female worms recovered from jird necropsies were frozen on
dry ice, thawed and ﬁxed for 20 min at room temperature with 3.2%
paraformaldehyde in phosphate buﬀered saline (pH 7) and 0.1% Tween
20 (PBS-T). Wolbachia content in the worm ovaries was quantiﬁed as
previously described (Serbus et al., 2012; Bakowski et al., 2019).
Brieﬂy, ovaries of the worms were dissected out and Wolbachia were
stained with 0.5 μM of each Wolbachia-speciﬁc 16S rRNA ﬂuorescence
in situ hybridization (FISH) probes labeled with Quasar 670 (Biosearch
Table 3
Dosing regimen for B. pahangi-infected jirds.
Group Treatment n = Dose (mg/kg) Daily doses Duration (d)
1 Vehicle 6 – QD 7
2 CBR417 6 40 QD 7
3 CBR490 6 40 QD 7
4 CBR490 6 20 QD 7
5 CBR490 5 10 QD 7
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Technologies) complementary to Wolbachia 16S rRNA (W2 (Heddi
et al., 1999) and Wpan1 (Bakowski et al., 2019), in the presence of
unlabeled helper probes (W2H1 and W2H2 (Heddi et al., 1999) and
Wpan1H1 and Wpan1H2 (Bakowski et al., 2019)). Stained ovaries were
mounted on slides using Vectashield with DAPI mounting medium
(Vector Laboratories Inc.). The central plane of each ovary near the
distal tip cell was imaged using the Leica SP5 confocal microscope with
a 63× objective and Wolbachia content was analyzed using Compart-
mental Analysis in HCS Studio (Thermo Fisher Scientiﬁc). Worm germ
cell nuclei were identiﬁed using DAPI signal and far red (Wolbachia 16S
rRNA FISH)-stained spots within all identiﬁed cells were selected based
on their signal intensity above background using the box detection
method and ﬁxed thresholding. Average Wolbachia spot total intensity
per worm cell from each ovary was normalized to averaged data ob-
tained from DMSO treated ovaries to determine % Wolbachia elimina-
tion (100 ∙ (mean DMSO – sample)/mean DMSO).
2.2.7. Transmission electron microscopy of female B. pahangi recovered at
necropsy
Female worms recovered from 2–3 jirds per group were ﬁxed in
2.5% glutaraldehyde, 2% paraformaldehyde in 0.1 M sodium cacody-
late buﬀer, pH 7.4 (EMS, USA). Worms were cut into 2–3 mm long
pieces in the ﬁxative and incubated for 3 h at room temperature and at
4 °C overnight. Samples were washed thoroughly in the buﬀer and post-
ﬁxed in 1% osmium tetroxide in 0.1 M sodium cacodylate buﬀer for 1 h.
Samples were then washed in the buﬀer, in distilled water and a series
of ethanol dilutions: 30%, 50% (with 5% uranyl acetate), 70%, 95%, for
10 min each, and twice with 100% ethanol for 20 min each. Samples
were inﬁltrated with a gradient of acetone-Embed 812 resin and em-
bedded in 100% resin. After sectioning the solidiﬁed blocks, ~70 nm
sections were stained with UranyLess (EMS, USA) and lead citrate fol-
lowed by observation using a FEI Tecnai 12 Spirit transmission electron
microscope (Microscopy core facility, NYBC).
2.3. qPCR analysis of Wolbachia from adult female B. pahangi
qPCR was performed to obtain the ratio of wsp to gst gene copy
number, as previously described (Halliday et al., 2014; McGarry et al.,
2004). Brieﬂy, individual adult female B. pahangi were ﬁxed in RNA-
later and stored at 4 °C. For Wolbachia, DNA was extracted from worm
samples using the DNeasy Blood and Tissue Kit (Qiagen) according to
manufacturer's instructions. Levels of B. pahangi Wolbachia wsp and B.
pahangi gst gene copy numbers were quantiﬁed using qPCR with Brugia-
speciﬁc primers. The following primers were used to amplify a 164 bp
internal sequence of the Wolbachia wsp gene (wsp primers): wsp 420
forward 5′ TGT TGG T(AG)T TGG T(GC)T TGG TG 3’; wsp 583 reverse 5′
AAC CAA A(AG)T AGC GAG C(CT)C CA 3′. The following primers were
used to amplify a 183 bp internal sequence of the Brugia gst gene (gst
primers): gst 1377 forward: 5′ TGC TCG CAA ACA TAG TAA TAG T 3′;
gst 1632 reverse: 5′ATC ACG GAC GCC TTC ACA G 3′.
2.4. Statistical analyses
As a primary eﬃcacy parameter, the reduction ofWolbachia from L.
sigmodontis female adult worms was determined. Furthermore, statis-
tical analyses on inhibition of embryogenesis and clearance of mf were
performed using GraphPad Prism software Version 8.12 (GraphPad
Software, San Diego, USA). Diﬀerences between multiple groups that
were not normally distributed were tested for statistical signiﬁcance
using Kruskal-Wallis followed by Dunn's multiple comparison test. P-
values ≤ 0.05 were considered statistically signiﬁcant. To determine
signiﬁcance of Wolbachia depletion in B. pahangi quantiﬁed using
Wolbachia-speciﬁc FISH-based staining, a one-way ANOVA with
Dunnett's correction for multiple comparisons was used in GraphPad
Prism version 8.0.1 (comparison between vehicle and all treatment
groups was preselected).
3. Results
3.1. Short course treatment of L. sigmodontis-infected jirds with CBR417
and CBR490 reduces Wolbachia levels
Based on the previously described eﬃcacy against Wolbachia using
short treatment durations with the quinazolines CBR417 and CBR490 in
the L. sigmodontis mouse model (Bakowski et al., 2019), we performed a
more detailed analysis of their eﬃcacy in the L. sigmodontis jird model
that included parasitological analysis and compared it to doxycycline
treatment given for 14 days.
In line with previous studies testing novel Wolbachia targeting
compounds, all tested treatment regimens with CBR417 and CBR490
did not lead to any statistically signiﬁcant decrease in the number of
adult worms recovered after 16 or 18 weeks after treatment (Bakowski
et al., 2019) (Supplementary Fig. 1). However, 4- and 7-day QD regi-
mens of 50 mg/kg CBR417 (Fig. 1A and B), as well as BID treatments
with 75 and 25 mg/kg CBR490 for 7 days (Fig. 1A and B) signiﬁcantly
reduced the Wolbachia load in the female worms by more than 99% in
comparison to untreated controls. Importantly, these CBR417 and
CBR490 treatment regimens were superior to a BID treatment of 40 mg/
kg doxycycline given for 14 days, which resulted in no Wolbachia re-
duction at 16 and 18 wpt in comparison to untreated controls (Fig. 1A
and B). Lower QD doses of 20 and 10 mg/kg CBR417 or CBR490 given
for 7 days did not deplete Wolbachia in the female worms and was
therefore not superior over doxycycline treatment (Fig. 1A and B).
These data indicate that QD administrations of 50 mg/kg CBR417 as
Fig. 1. Short course treatment of L. sigmodontis-
infected jirds with CBR417 and CBR490 reduces
Wolbachia levels. Wolbachia ftsZ/ﬁlarial actin ratio
of female adult worms isolated from jirds infected
with L. sigmodontis that have been treated with
doxycycline (DOX), CBR417, CBR490, vehicle con-
trol or left untreated. A: 13-week-infected jirds were
either left untreated or treated twice a day (BID)
with 40 mg/kg (mpk) doxycycline for 14 days, once
per day (QD) with 50 mg/kg CBR417 for 4 days or
BID with 75 or 25 mg/kg CBR490 for 7 days. B: 16-
week-infected jirds were either treated BID with
vehicle control for 7 days, BID with 40 mg/kg dox-
ycycline for 14 days, QD with 50, 20 or 10 mg/kg
CBR417 for 7 days, BID with 25 mg/kg CBR490 for 7
days, or QD with 20 or 10 mg/kg CBR490 for 7 days.
Jirds were sacriﬁced 16 (A) or 18 (B) weeks after
treatment. N = 5–6 per group. Analysis for statistical signiﬁcance was done by Kruskal-Wallis followed by Dunn's multiple comparison post-hoc test. **P < 0.01;
****P < 0.0001.
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short as 4 days and BID administrations of 75 and 25 mg/kg CBR490 for
7 days are highly eﬃcacious in depleting Wolbachia endosymbionts.
3.2. Embryogenesis is inhibited by CBR417 and CBR490 treatment in the L.
sigmodontis jird model
Since Wolbachia bacteria are essential for ﬁlarial fecundity, em-
bryogenesis was analyzed in female adult worms isolated from jirds
infected with L. sigmodontis that were treated with diﬀerent regimens of
CBR417 and CBR490 and compared to untreated and doxycycline-
treated animals (Hoerauf et al., 2000). Embryogenesis within the uteri
of female worms from animals treated with 50 mg/kg of CBR417 QD for
4 and 7 days or with CBR490 BID at 75 or 25 mg/kg for 7 days sig-
niﬁcantly inhibited embryogenesis and resulted mainly in degenerated
embryos (Fig. 2A and B). Lower QD doses of CBR417 (20 mg/kg, 7
days) and CBR490 (10 mg/kg, 7 days) had no signiﬁcant impact on
oocyte, pretzel, and stretched mf counts (Fig. 2B), but resulted in a
signiﬁcant increase in degenerated embryos in CBR417 (20 mg/kg QD
for 7 days)-treated animals and a signiﬁcant reduction in the morula
stages of CBR490 (10 mg/kg QD for 7 days)-treated animals compared
to vehicle controls. Doxycycline treatment reduced the total number of
embryonic stages in comparison to vehicle/untreated controls, leading
to statistically signiﬁcant changes in one of the two experiments in
regard to the number of stretched mf in the uteri (Fig. 2A) and pretzel
stages (Fig. 2B). These data indicate that treatments of 4 and 7 days
with CBR417 or CBR490, respectively, can lead to a complete inhibition
of the embryogenesis in the L. sigmodontis jird model.
3.3. Microﬁlariae levels decline in response to CBR417 and CBR490
treatment
Since embryogenesis was inhibited in female adult L. sigmodontis
worms after 4–7 days of CBR417 and CBR490 treatment, the kinetics of
peripheral blood mf clearance were also investigated. Starting 8–10
weeks after treatment, peripheral blood mf numbers began to decline in
animals that received CBR417 at 50 mg/kg QD for 4 or 7 days, as well
as 20 mg/kg for 7 days (Fig. 3A and B). Similarly, treatment with
CBR490 given BID at 75 mg/kg and 25 mg/kg also started to reduce the
mf levels around 8–10 wpt. Notably, CBR417 given at 50 mg/kg QD for
4 or 7 days and CBR490 given BID at 75 or 25 mg/kg completely
cleared the peripheral blood mf by 16–18 wpt, while treatment with
40 mg/kg doxycycline given BID for 14 days initially cleared mf in 9
out of 11 animals by 12 wpt, but then led to a rebound of the mf with 5
out of 11 animals being mf positive by 16–18 wpt (Fig. 3A and B).
Fig. 2. Embryogenesis is inhibited by CBR417 and CBR490 treatment in the L. sigmodontis jird model. Embryonic stages (oocyte, morula, pretzel, stretched mf
and degenerated embryos) per female adult worms isolated from jirds infected with L. sigmodontis that were treated with doxycycline (DOX), CBR417, CBR490,
vehicle control or left untreated. A: 13-week-infected jirds were either left untreated or treated bi-daily (BID) with 40 mg/kg doxycycline for 14 days, once per day
(QD) with 50 mg/kg CBR417 for 4 days or BID with 75 or 25 mg/kg CBR490 for 7 days. B: 16-week-infected jirds were either treated BID with vehicle control for 7
days, BID with 40 mg/kg doxycycline for 14 days, QD with 50 or 20 mg/kg CBR417 for 7 days, or QD with 10 mg/kg CBR490 for 7 days. Jirds were sacriﬁced 16 (A)
or 18 (B) weeks after treatment. Analysis for statistical signiﬁcance was done by Kruskal-Wallis followed by Dunn's multiple comparison post-hoc test.
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Lower QD doses of CBR490 and CBR417 of 10–20 mg/kg did not sig-
niﬁcantly reduce the mf load in comparison to the vehicle controls
(Fig. 3B). Importantly, the slow decline in the mf burden of CBR417 and
CBR490-treated animals in addition to the shown inhibition of the
embryogenesis indicate that both candidates lack a strong direct acting
microﬁlaricidal activity; this is important from the point of view of
reducing risk of potential serious adverse events.
3.4. Short course treatment of B. pahangi-infected jirds reduces
microﬁlarial shedding
In parallel with the L. sigmodontis jird model, drug eﬃcacy was
analyzed in jirds infected with B. pahangi. Similar to the results ob-
served for the L. sigmodontis-infected jirds, adult worm recovery from B.
pahangi-infected jirds treated with CBR417 nor CBR490 was not af-
fected at the time of necropsy (17 wpt). However, the number of mf
from the peritoneal cavities of B. pahangi-infected jirds was signiﬁcantly
lower (P < 0.05) in animals treated with 40 mg/kg CBR417 QD for 7
days but not with the other treatment groups (Fig. 4). After female
worms were recovered from the peritoneal cavities, each worm was
incubated individually overnight at 37 °C with 5% CO2 and the number
of mf released by each female worm was counted. Consistent with the
reduced number of mf recovered at necropsy, 89% of the females from
animals treated with CBR417 did not shed mf overnight (Table 4).
3.5. Development of microﬁlariae are signiﬁcantly reduced in animals
treated with both CBR417 and CBR490
Embryograms revealed that the number of stretched mf were sig-
niﬁcantly reduced in animals treated with CBR417 (P < 0.001) and
CBR490 (P < 0.01) when both groups were dosed at the same dosage
of 40 mg/kg QD for 7 days. CBR417 also caused an increase in the
number of deformed embryos (P < 0.01) (Fig. 5).
3.6. Transmission electron micrographs reveal damage to B. pahangi
microﬁlariae developing within the treated female ovaries
Consistent with the results of the embryograms and reduced number
of mf that were shed from female B. pahangi worms that were recovered
at necropsy, ultrastructural analysis revealed extensive damage in
ovaries of female worms from jirds treated with CBR417 (40 mg/kg QD
for 7 days). Numerous vacuoles, large empty tissue spaces and irregular
membranous structures were observed in embryos from female worms
recovered from these treated animals compared to the ultrastructural
organization seen in worms from the vehicle group (Fig. 6).
3.7. Fluorescence analysis reveals signiﬁcant reduction of Wolbachia in B.
pahangi female worms from jirds treated with CBR417 and CBR490
Ovaries were assessed for Wolbachia titers from individual female
worms recovered from jirds at necropsy (17 wpt) using Wolbachia-
speciﬁc 16S rRNA FISH staining and high content image analysis.
Female worms recovered from animals treated with 40 mg/kg QD x 7
days of CBR417 or CBR490 had signiﬁcantly lower Wolbachia titers
(> 99.99% and 92.77% mean Wolbachia elimination, respectively;
P < 0.0001) compared to worms from vehicle treated animals (Fig. 7).
3.8. CBR417 signiﬁcantly reduces Wolbachia titers in adult female and
male B. pahangi ﬁlariae
CBR417 given to B. pahangi-infected jirds at doses of 40 mg/kg QD
for 7 days had a signiﬁcant eﬀect on Wolbachia titers in both male and
female worms (Fig. 7A and B). qPCR analysis of individual worms
showed there was a> 99% reduction in titers in female and male
worms compared to worms from vehicle-treated animals (Fig. 8A and
B).
Fig. 3. Microﬁlariae levels decline in response to CBR417 and CBR490
treatment. Mf count per 10 μL of blood drawn from jirds infected with L. sig-
modontis and that have been treated with doxycycline (DOX), CBR417, CBR490,
vehicle control or left untreated. A: 13-week-infected jirds were either left
untreated ( ) or treated bi-daily (BID) with 40 mg/kg doxycycline for 14 days
( ), once per day (QD) with 50 mg/kg CBR417 for 4 days ( ) or BID with 75 ( )
or 25 mg/kg ( ) CBR490 for 7 days. B: 16-week-infected jirds were either
treated BID with vehicle control for 7 days ( ), BID with 40 mg/kg doxycycline
for 14 days ( ), QD with 50 ( ), 20 ( ) or 10 ( ) mg/kg CBR417 for 7 days, QD
with 20 ( ) or 10 ( ) mg/kg CBR490 for 7 days or BID with 25 mg/kg CBR490
for 7 days ( ). Jirds were sacriﬁced 16 (A) or 18 (B) weeks after treatment.
N = 5–6 per group.
Fig. 4. B. pahangi microﬁlariae recovered at necropsy are signiﬁcantly
reduced in jirds treated with 40 mg/kg CBR417 given QD for 7 days
(P < 0.05). Mf were recovered from the peritoneal cavities and counted from
each jird 17 wpt.
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3.9. CBR417 and CBR490 exposures achieved in jirds during in vivo
experiments
Sparse PK sampling during in vivo eﬃcacy experiments carried out
in jirds infected with either L. sigmodontis (Supplement 2A) or B. pa-
hangi (Supplement 2B) conﬁrmed relative exposures of CBR417 and
CBR490 achieved during these studies. Exposures of both compounds
matched previously-published PK proﬁles observed in mice (Bakowski
et al., 2019) and a slight accumulation of CBR417 was observed after
both 4 (Supplement 2A) and 7 (Supplement 2B) days of QD dosing.
Notably, lower doses of CBR490 in B. pahangi-infected jirds (20 or
10 mg/kg 7 days QD) (Supplement 2B) failed to reach exposures
markedly above anti-B. pahangi Wolbachia EC50 previously determined
ex vivo (Bakowski et al., 2019).
4. Discussion
Our study demonstrates that the quinazoline drug candidates
CBR417 and CBR490 are highly eﬀective in two rodent models of ﬁ-
lariasis. In agreement with a recently published study (Bakowski et al.,
2019), short term regimens of 7 days or less with CBR417 and CBR490
achieved signiﬁcantWolbachia depletions of> 99%. While the previous
study by Bakowski et al. focused on the depletion of the Wolbachia
endosymbionts ~4 weeks after treatment, the present study used two
models of chronic ﬁlariasis, which allowed a long-term analysis of the
impact of the CBR417 and CBR490 treatment regimens on Wolbachia
depletion as well as adult worm burden, microﬁlaremia and embry-
ogenesis.
Limitations of our study are due to the usage of surrogate ﬁlarial
species in animal models for the preclinical analysis of drugs intended
for human ﬁlariasis, with ﬁlarial species that may possess a diﬀerent
susceptibility for the drug candidates, altered PK/PD relations in the
rodent hosts and diﬀerences in the anatomical locations where the adult
ﬁlariae are found. Nevertheless, L. sigmodontis and Brugia rodent models
have been used in a range of preclinical studies, including a human
progression study with the preclinical candidate ABBV-4083 (DNDi,
2019; Fischer et al., 2019; Hong et al., 2019; Hübner et al., 2019a;
Jacobs et al., 2019; Taylor et al., 2019). Doxycycline, the ﬁrst proven
safe macroﬁlaricidal treatment for human ﬁlariasis was also tested in
the L. sigmodontis model and was comparable to what was found in
human studies (Hoerauf et al., 1999), i.e. clearance of Wolbachia, mi-
croﬁlaremia and inhibition of embryogenesis, indicating that suﬃcient
drug exposures can be achieved in subcutaneous nodules of oncho-
cerciasis or lymph vessels in the case of lymphatic ﬁlariasis. Given the
suboptimal doxycycline treatment regimen of only 2 weeks in our
present study, we did not observe a clearance of Wolbachia within the
female adult worms at 16–18 wpt. A previous study from our group
showed that this doxycycline regimen leads to an initial reduction of
Wolbachia, which is not maintained and leads to a rebound ofWolbachia
(Hübner et al., 2019b). Accordingly, this doxycycline regimen also did
not completely clear the peripheral mf.
In line with previous studies by our groups and others (Hong et al.,
2019; Jacobs et al., 2019; Taylor et al., 2019), no diﬀerences were
observed in the adult worm burden following all tested anti-Wolbachia
treatment regimens (Bakowski et al., 2019; Taylor et al., 2019), in-
cluding those with CBR490 and CBR417. Macroﬁlaricidal eﬃcacy of
Wolbachia-targeting compounds is slow acting and occurs in humans
harboring ﬁlarial infection only after ~2 years (Hoerauf et al., 2009,
2011; Debrah et al., 2015). Nevertheless, results from the present study
indicate that in line with the successful depletion of Wolbachia in the
adult ﬁlarial worms, a gradual decline of peripheral microﬁlaremia
over a period of 16–18 weeks was observed that was accompanied by
the complete inhibition of embryogenesis. Such a slow removal of
peripheral blood mf is beneﬁcial, as it may prevent drug-induced ser-
ious adverse events that are associated with a fast clearance of the mf,
for example, as they occur following DEC treatment in onchocerciasis
Table 4
CBR417 reduced the number of B. pahangi microﬁlariae that were released from female worms recovered from jirds at necropsy. Female worms were recovered from
jirds and cultured overnight to assess the number of mf released by each worm. 89% of female worms from animals treated with CBR417 did not shed mf (8 of 9
female worms).
Treatment # females shedding mf # females not shedding mf % females not shedding mf
Vehicle 7 9 56%
CBR417 QD 40 mpk x 7d 1 8 89%
CBR490 QD 40 mpk x 7d 6 6 50%
CBR490 QD 20 mpk x 7d 13 4 24%
CBR490 QD 10 mpk x 7d 8 4 33%
Fig. 5. Embryograms of female B. pahangi show that CBR417 and CBR490 aﬀect late stages of developing mf.Both CBR417 and CBR490 (40 mg/kg QD for 7
days) signiﬁcantly reduced the number of later-staged mf. Female worms recovered from jirds treated with CBR417 also had signiﬁcantly more degenerated embryos
in their ovaries. Embryonic stages (oocytes, embryos, pre-mf, stretched mf and degenerated embryos) per female adult worm were removed from jirds infected with
B. pahangi and counted from the ovaries and uteri of individual worms. Results are shown as mean relative frequencies of embryonic stages ± SEM
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patients. Furthermore, Wolbachia-targeting drugs should not impact L.
loa, as this ﬁlarial species lacks the endosymbiotic bacteria (Desjardins
et al., 2013), preventing the risk of serious adverse events in areas co-
endemic for loiasis. Although we did not conﬁrm that CBR490 and
CBR417 treatments deplete Wolbachia from male L. sigmodontis worms,
our experiments with B. pahangi indicate that both compounds are ef-
fective in male as well as female ﬁlariae. Nevertheless, pathology in
onchocerciasis is driven by the dying mf and not the adult ﬁlariae, in-
dicating that sterilization of the female adult worms and lack of mf
release should prevent the occurrence or progression of pathology.
Comparison of the diﬀerent regimens used for CBR490 and CBR417
in our study further showed that CBR417 given QD at 50 mg/kg for as
short as 4 days and CBR490 given BID at doses as low as 25 mg/kg for 7
days mediated the clearance of> 99% of Wolbachia, leading to ami-
croﬁlaremia and complete inhibition of embryogenesis in all animals
treated. In contrast, QD treatments with CBR490 or lower doses of
10–20 mg/kg CBR417 were not eﬃcacious in line with inadequate PK
exposure achieved at those lower doses in relation to EC90s against B.
pahangi Wolbachia previously determined in ex vivo experiments
(Bakowski et al., 2019). Moreover, our study demonstrated the im-
portance of longer observation periods of at least 4 months after
treatment; this was illustrated in the suboptimal 2-week treatment with
doxycycline and the low dosages of CBR417, which led to an initial
drop in peripheral blood mf levels (Fig. 3) and a reduction of embryonic
stages (Fig. 2), and a later rebound of mf levels (Fig. 3).
This was similarly shown in a previous study where the anti-
Wolbachia drug candidate ABBV-4083 was tested in the L. sigmodontis
model (Hübner et al., 2019b). Mouse models used in the earlier pre-
clinical studies were predictive of the initialWolbachia-depleting eﬀect,
but were limited in analysis of the long-term eﬀects, which is essential
to observe the possible rebound of Wolbachia and mf. Therefore, the
impact of anti-wolbachial compound treatment during a patent, chronic
infection and on ﬁlarial embryogenesis as well as kinetics of mf clear-
ance can only be analyzed in jirds, as they have an increased
Fig. 6. Transmission electron micrographs re-
veal extensive damage to the developing B. pa-
hangi microﬁlariae in ovaries of worms from
jirds treated with CBR417 QD 40 mg/kg for 7
days. N = nucleus; N* = abnormal nucleus;
Mf = microﬁlariae developing in uteri;
Mf* = abnormal microﬁlariae in uteri; bar = 4 μm.
Fig. 7. High content imaging of ovaries show a highly signiﬁcant reduc-
tion in Wolbachia from female B. pahangi worms recovered from jirds
treated with 40 mg/kg QD x 7 days CBR417 (P < 0.0001) and CBR490
(P < 0.0001). Ovaries from individual females were removed and stained
with Wolbachia speciﬁc 16S rRNA probes using ﬂuorescence in situ hybridiza-
tion (FISH) and DAPI. Ovaries were imaged using confocal microscopy and
Wolbachia quantiﬁed using high content image analysis. Means ± SD (average
signal from 1 to 2 ovaries from 5 to 7 worms per treatment) are shown, and
mean elimination (%) is reported. To assess signiﬁcance between the vehicle
control and treatment groups a one-way ANOVA with Dunnett's multiple
comparisons test was used (****P < 0.0001).
Fig. 8. CBR417 is highly eﬀective in reducing Wolbachia titers in adult B. pahangi. qPCR analysis of individual worms showed there was a>99% reduction in
titers in female (A) and male (B) worms compared to worms from vehicle-treated animals (****P < 0.0001).
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susceptibility for infection with L. sigmodontis as well as B. pahangi in
comparison to wildtype mice (Morris et al., 2013). Thus, the two jird
models of ﬁlarial infection used in the current study are a valuable,
advanced model system to assess the longer-term impact thatWolbachia
have on microﬁlarial output and disruption of female fecundity.
In summary, our study demonstrates the value of the two jird
models that allow chronic, patent ﬁlarial infections to assess anti-wol-
bachial compounds and their impact on long-term Wolbachia and mf
clearance as well as embryogenesis. Especially in regard to the potential
rebound of Wolbachia and mf using suboptimal treatment regimens,
such models are essential. Using these models, we demonstrate that
CBR417 and CBR490 are two promising novel drug candidates that
deplete Wolbachia endosymbionts of ﬁlarial nematodes and clear cir-
culating mf via the disruption of embryogenesis. Thus, CBR417 and
CBR490 are candidates for the treatment of human ﬁlariasis that allow
treatment regimens of 7 days or less.
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